Prevention

• flecainide - at least 50 mg twice daily ^a

Why?

• Flecainide reduces symptomatic arrhythmias better than placebo. ^a In addition the interval between attacks is longer (on average 17 days longer). ^a
• Fewer patients on flecainide withdraw than on quinidine ^a

Paroxysmal atrial flutter: flecainide prevents symptomatic attacks and causes fewer side-effects than quinidine

Patient	Treatment	Comparison	Outcome	CER	RRR (95% CI)	NNT (95% CI)
paroxysmal AF a	flecainide 50 mg twice daily	placebo	no attacks	7.1%	-600% (-2700% to 75%)	2 (2 to 5)
symptomatic paroxysmal AF or flutter a	flecainide	quinidine	discontinued medication due to adverse effects at 12 months	30%	40% (4% to 62%)	8 (4 to 88)